Corporate Investor

MedImmune Ventures

AstraZeneca, established in 1998, is a pharmaceutical company headquartered in Cambridge, UK. It develops medicines for areas like cancer and cardiovascular disease. AstraZeneca launched Evinova, a HealthTech business.

MedImmune Ventures

AstraZeneca, established in 1998, is a pharmaceutical company headquartered in Cambridge, UK. It develops medicines for areas like cancer and cardiovascular disease. AstraZeneca launched Evinova, a HealthTech business.

General information

Firm type

Corporate Investor

Year founded

1998

AUM

Location

Region

Country

City

Cambridge

Corporate office

1 Francis Crick Avenue Cambridge Biomedical Campus

Frequently asked questions

What is MedImmune Ventures?

MedImmune Ventures is a corporate investor headquartered in Cambridge.

When was MedImmune Ventures founded?

MedImmune Ventures was founded in 1998.

Where is MedImmune Ventures headquartered?

MedImmune Ventures is headquartered in Cambridge.

What does Altss track for MedImmune Ventures?

Altss maintains an OSINT-verified profile of MedImmune Ventures covering investment focus (ESG policy, ticket size, target IRR, currency preference, regional focuses, industry focuses, technological focuses), team (service providers and advisors), deals (company deals and fund commitments), assets (real estate, public market positions, private companies, art and cultural holdings, philanthropy and foundations), and network (club memberships, associations, and event participation). Detailed values are available to Altss subscribers.

What is MedImmune Ventures's website?

MedImmune Ventures's public website is www.astrazeneca.com. Verified contact details for principals and decision-makers are available to Altss subscribers.

What type of firm is MedImmune Ventures?

MedImmune Ventures is classified by Altss as a Corporate Investor.

How does Altss source intelligence on MedImmune Ventures?

Altss combines OSINT (open-source intelligence) with regulatory filings, public disclosures, and licensed data partners. Source provenance is tracked to support compliance-ready research workflows.

How fresh is the Altss profile for MedImmune Ventures?

MedImmune Ventures's profile is part of Altss's continuous-refresh dataset, with a full update cycle at least every 30 days and priority changes applied as new information is verified.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classLive OSINT deal alerts
Start your free trial

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo